Windtree Therapeutics (NASDAQ:WINT) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are being filed herewith:
WINDTREE THERAPEUTICS INC /DE/ Exhibit
EX-4.1 2 ex_187838.htm EXHIBIT 4.1 ex_182864.htm Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT WINDTREE THERAPEUTICS,…
To view the full exhibit click here
About Windtree Therapeutics (NASDAQ:WINT)
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.